Blood Res.  2018 Jun;53(2):169-172. 10.5045/br.2018.53.2.169.

Long-term control of refractory follicular lymphoma after treatment of secondary acute promyelocytic leukemia with arsenic trioxide (As₂O₃) and all-trans retinoic acid (ATRA)

• Jain P
• Konoplev S
• Benjamini
• Romagura J
• Burger JA

• KMID: 2451039
• DOI: http://doi.org/10.5045/br.2018.53.2.169

Abstract

No abstract available.

MeSH Terms

Arsenic*
Leukemia, Promyelocytic, Acute*
Lymphoma, Follicular*
Tretinoin*
Arsenic
Tretinoin

Figure

• 

  Fig. 1 Mammogram showing extramedullary relapse of follicular lymphoma in the breast (A). Hematoxylin and eosinophil (H&E) staining of breast biopsy showing follicular lymphoma (B, ×100).

• 

  Fig. 2 Positron emission tomography scans showing response to all-trans retinoic acid (ATRA) with arsenic trioxide therapy: left axillary lymph node mass before (A) and after therapy (B), hematoxylin and eosinophil (H&E) staining of axillary lymph node showing follicular lymphoma (C, ×100), immunohistochemistry showing positive Bcl2 staining (D, ×100), bone marrow showing acute promyelocytic leukemia cells with multiple auer rods (E, ×1,000).

Reference

1. Sehn LH, Fenske TS, Laport GG. Follicular lymphoma: prognostic factors, conventional therapies, and hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2012; 18:S82–S91. PMID: 22226118.

2. Mi JQ, Li JM, Shen ZX, Chen SJ, Chen Z. How to manage acute promyelocytic leukemia. Leukemia. 2012; 26:1743–1751. PMID: 22422168.

3. Chang JE, Voorhees PM, Kolesar JM, et al. Phase II study of arsenic trioxide and ascorbic acid for relapsed or refractory lymphoid malignancies: a Wisconsin Oncology Network study. Hematol Oncol. 2009; 27:11–16.

4. Zhao H, Sun G, Kong D, et al. A phase II study of arsenic trioxide in patients with relapsed or refractory malignant lymphoma. Med Oncol. 2015; 32:79. PMID: 25698531.

5. Takahashi S. Combination therapy with arsenic trioxide for hematological malignancies. Anticancer Agents Med Chem. 2010; 10:504–510. PMID: 20812901.

6. Berenson JR, Matous J, Swift RA, Mapes R, Morrison B, Yeh HS. A phase I/II study of arsenic trioxide/bortezomib/ascorbic acid combination therapy for the treatment of relapsed or refractory multiple myeloma. Clin Cancer Res. 2007; 13:1762–1768. PMID: 17363530.

7. Gill H, Au WY, Cheung WW, Lee EY, Kwong YL. Oral arsenic trioxide-based regimen as salvage treatment for relapsed or refractory mantle cell lymphoma. Ann Oncol. 2014; 25:1391–1397. PMID: 24728036.

8. Lo RK, Kwong YL. Arsenic trioxide suppressed mantle cell lymphoma by downregulation of cyclin D1. Ann Hematol. 2014; 93:255–265. PMID: 23949314.

9. Yoon JS, Hwang DW, Kim ES, et al. Anti-tumoral effect of arsenic compound, sodium metaarsenite (KML001), in non-Hodgkin's lymphoma: an in vitro and in vivo study. Invest New Drugs. 2016; 34:1–14. PMID: 26581399.

10. Niitsu N, Higashihara M, Honma Y. Human B-cell lymphoma cell lines are highly sensitive to apoptosis induced by all-trans retinoic acid and interferon-gamma. Leuk Res. 2002; 26:745–755. PMID: 12191570.

11. Singh AT, Evens AM, Anderson RJ, et al. All trans retinoic acid nanodisks enhance retinoic acid receptor mediated apoptosis and cell cycle arrest in mantle cell lymphoma. Br J Haematol. 2010; 150:158–169. PMID: 20507312.

12. Barna G, Sebestyén A, Weischede S, et al. Different ways to induce apoptosis by fenretinide and all-trans-retinoic acid in human B lymphoma cells. Anticancer Res. 2005; 25:4179–4185. PMID: 16309214.